ArticleBMJ open respiratory research2025
Impact of body mass index on outcomes of non-cystic fibrosis bronchiectasis.
Article in BMJ open respiratory research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Comparison of chest CT-derived muscle mass and body mass index in assessing disease severity and outcomes in non-cystic fibrosis bronchiectasis.BMC pulmonary medicine · 2026Article
- The Effects of Obesity on Lung Physiology, the Prevalence and Severity of Chronic Pulmonary Diseases, and Inhalation Treatment.Drug design, development and therapy · 2025Review
- Nutritional management in bronchiectasis: A practical guide for clinicians.Therapeutic advances in respiratory diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLow body mass index (BMI) is associated with poor prognosis in patients with non-cystic fibrosis (non-CF) bronchiectasis. However, the impact of being overweight or obese on clinical outcomes of these patients remains controversial. MATERIALS AND
methodsThis retrospective cohort study was conducted using TriNetX. Patients diagnosed with non-CF bronchiectasis between 2012 and 2022 were identified. The eligible population was divided into four groups based on their BM. Propensity score matching (PSM) was used to balance baseline demographic and clinical characteristics between study groups. The primary outcome of interest was all-cause mortality during a 5-year follow-up period.
resultsA total of 14 469 patients were included in the analysis. After PSM, the underweight group exhibited significantly higher all-cause mortality compared with those with a normal BMI (24.3% vs 15.3%; HR 1.83; 95% CI 1.49 to 2.25; p=0.0150). Conversely, both the overweight (16.6% vs 21.4%; HR 0.77; 95% CI 0.68 to 0.88; p=0.0138) and obese groups (16.8% vs 20.2%; HR 0.79; 95% CI 0.71 to 0.87; p=0.0356) demonstrated lower all-cause mortality rates. In addition, consistently higher risks in the underweight group and lower risks in the overweight and obese groups were observed for several critical health outcomes, including the need for critical care service, incidence of pneumonia, tuberculosis or non-tuberculous mycobacterial infection, acute exacerbation of bronchiectasis, acute respiratory failure and ventilator use.
conclusionsBeing underweight is a risk factor for all-cause mortality in patients with non-CF bronchiectasis and the aforementioned clinical outcomes. Conversely, overweight and obesity are associated with lower all-cause mortality rates and better outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.